# SUPPLEMENTAL MATERIAL

**Table S1.** Eligibility criteria of the PLATO trial.

| *Inclusion criteria* | *Exclusion criteria* |
|---|---|
| • STEMI (persistent ST-elevation ≥1 mm in ≥2 contiguous leads or new LBBB), with primary PCI planned<br><br>***or:***<br><br>• NSTE-ACS with ≥2 of the following:<br>▪ ST-segment changes on ECG indicating ischemia (ST-depression or transient elevation ≥1 mm in two or more contiguous leads)<br>▪ Positive biomarker indicating myocardial necrosis (troponin or CK-MB above the upper limit of normal)<br>▪ ≥1 of the following:<br>o ≥60 years of age<br>o Previous MI or CABG<br>o Coronary artery disease with ≥50% stenosis in ≥2 vessels<br>o Previous ischemic stroke/TIA, carotid stenosis (≥50%), or cerebral revascularization<br>o Diabetes mellitus<br>o Peripheral artery disease<br>o Chronic renal dysfunction | • Contraindication to clopidogrel (e.g. hypersensitivity, moderate or severe liver disease, bleeding, major surgery within 30 days)<br>• Oral anticoagulant therapy<br>• Fibrinolytic therapy planned or within the previous 24 hours<br>• Concomitant therapy with strong CYP3A inhibitors, CYP3A substrates with narrow therapeutic indices, or strong CYP3A inducers<br>• Index event is an acute complication of PCI<br>• PCI after index event and before first study dose<br>• Increased risk of bradycardiac events<br>• Dialysis required<br>• Known clinically important thrombocytopenia<br>• Known clinically important anemia<br>• Any other condition that may put the patient at risk or influence study results in the investigators' opinion (e.g. cardiogenic shock, severe hemodynamic instability, active cancer)<br>• Participation in another drug or device study within 30 days<br>• Pregnancy or lactation |

**Figure S1.** Selection of study population.




**Figure S2.** Importance of variables included in the ordinary least squares model for GDF-15 levels at 1 month, where importance is measured as $Chi^2$ – df.